Julia Belone Lopes

Julia Belone Lopes

Auto-generated profile, based on publicly available information

Julia Belone Lopes

Department of Medical Oncology, Hospital de Base de São José do Rio Preto, São José do Rio Preto, Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
RRRodrigo Fellipe Rodrigues
Rodrigo Fellipe Rodrigues
RHRaquel Cristina Trovo Hidalgo
Raquel Cristina Trovo Hidalgo
SBSávio Batista
Sávio Batista
JLJúlia Belone Lopes
Júlia Belone Lopes
GMGabriel Paulo Mantovani
Gabriel Paulo Mantovani
SOSonia Maria Oliani
Sonia Maria Oliani
Mechanical thrombectomy (MT) is a key therapy for acute ischemic stroke (AIS), improving survival and functional outcomes. However, the variability in results highlights the need for predictive markers to refine patient selection. Biomarkers reflecting inflammation and metabolic stress are gaining recognition for their role in AIS and MT outcomes. To systematically review and synthesize the evidence on biomarkers associated with clinical outcomes in AIS patients undergoing MT. Specific aims include evaluating their relationship with functional recovery (mRS), mortality, infarct volume, hemorrhagic transformation, and complications such as malignant brain edema (MBE) and delayed cerebral ischemia (DCI). A systematic review of the literature was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement to identify studies evaluating biomarkers in MT. The PubMed and Embase databases were searched using the following terms: (Marker OR biomarker*) AND (Mechanical Thrombectomy OR endovascular) AND Stroke. Of 2,834 articles identified, 86 met inclusion criteria. Several biomarkers, such as C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), adenosine deaminase (ADA), neuron-specific enolase (NSE), and matrix metalloproteinase-9 (MMP-9), were consistently associated with worse functional outcomes, increased mortality, and higher risk of complications including hemorrhagic transformation and MBE. Multiple biomarkers demonstrate prognostic value in AIS patients undergoing MT. These findings may support risk stratification and individualized care, though further prospective studies are needed to integrate these biomarkers into the clinical practice.

1 August 2025 in JCO Global Oncology
Verified
Journal Article
Closed access
JLJulia Belone Lopes
Julia Belone Lopes
ASAna Elisa Sanches
Ana Elisa Sanches
BDBeatriz de Menezes Dobbert
Beatriz de Menezes Dobbert
LFLorena Forner
Lorena Forner
JNJoão Pedro Homse Netto
João Pedro Homse Netto
DADaniel Vilarim Araujo
Daniel Vilarim Araujo
PURPOSE: Abiraterone acetate (AA) is approved for prostate cancer at a standard dose of 1,000 mg fasting. Because of a significant food effect, a lower dose (250 mg with food—AA low dose [AALD]) shows similar efficacy at 75% lower cost. In Brazil, 80% of patients rely on the public health care system, which does not cover the standard dose. Hospital de Base has been using AALD since March 2021. MATERIALS AND METHODS: We retrospectively reviewed patients with metastatic castration-resistant prostate cancer (mCRPC) who received AALD at any treatment line, regardless of previous chemotherapy, between March 2021 and May 2023. The primary end point was prostate-specific antigen (PSA) response rate (RR; defined as a decrease of ≥50% in PSA level after 12 weeks of treatment). Secondary end points included time to treatment failure (TTF), overall survival (OS), and PSA RR ≥50% at nadir. RESULTS: Ninety-six patients were included. Sixty-three patients (65.6%) received AALD in mCRPC first-line. After a median follow-up of 24.4 months, 53 patients (60.2%) achieved the primary end point, and 65 (69.9%) achieved a PSA reduction of ≥50% at nadir. Patients treated with AALD pre-docetaxel in the mCRPC had a higher PSA response at 12 weeks (68.3% v 40%, P = .015) and at nadir (76.1% v 53.8%, P = .036). First-line AALD was associated with better PSA responses. The median TTF was 7.9 months and the median OS was 20.6 months. Achieving a ≥50% PSA response at 12 weeks was associated with improved TTF (13.6 v 4.6 months, hazard ratio [HR] = 0.37, P < .001) and OS (28.9 v 12.2 months, HR = 0.44, P = .004). CONCLUSION: AALD showed meaningful efficacy and survival outcomes. We support AALD use, especially where standard dosing is unaffordable.